Literature DB >> 29263723

The effectiveness of intra-articular injections of Hyalubrix® combined with exercise therapy in the treatment of hip osteoarthritis.

Giulia Letizia Mauro1, Antonino Sanfilippo2, Dalila Scaturro1.   

Abstract

PURPOSE: Osteoarthritis (OA) is the most common joint disorder in the elderly, causing significant pain which negatively affects mobility and quality of life. The aim of the study was to assess the effectiveness of ultrasound image-guided intra-articular injections of Hyalubrix® combined with exercise therapy in the treatment of hip osteoarthritis.
METHODS: This was a single site, prospective, open-label, Investigator-initiated study. Forty patients were enrolled and received three ultrasound image-guided injections of Hyalubrix®, 45 days apart, combined with three sessions a week of physical therapy (proprioceptive rehabilitation of the lower limbs; gait training; balance training) up to a total of 30 sessions (10 weeks), starting from one week after the first injection.
RESULTS: The primary objective was to achieve a lasting reduction in OA symptoms related to pain during activity. During the course of the study the pain perceived by the patient during activity dropped from a mean value of 6.94 cm to a mean value of 1.46 cm and showed a statistically significant decrease from visit 1 compared to baseline (p < 0.05) which was confirmed at all the subsequent time points. Significant improvements were also observed in the evaluation of the secondary objectives: hip disability; OA-related pain at rest; daily functioning and NSAIDs intake.
CONCLUSIONS: Results from this study including 40 patients for a total of 65 treated hips demonstrate a significant improvement in OA-related pain, hip disability, and patient's daily functioning as well as a reduction in NSAIDs intake. Patients suffering from hip OA seem to benefit from the treatment with Hyalubrix® injections plus exercise therapy.

Entities:  

Keywords:  hip osteoarthrosis; hyaluronic acid; physical therapy; viscosupplementation

Year:  2017        PMID: 29263723      PMCID: PMC5726199          DOI: 10.11138/ccmbm/2017.14.1.146

Source DB:  PubMed          Journal:  Clin Cases Miner Bone Metab        ISSN: 1724-8914


  16 in total

1.  Comparison of two different viscosupplements in knee osteoarthritis -- a pilot study.

Authors:  M Bayramoğlu; M Karataş; N Cetin; N Akman; S Sözay; A Dilek
Journal:  Clin Rheumatol       Date:  2003-05       Impact factor: 2.980

2.  Screening for hip and knee osteoarthritis in the general population: predictive value of a questionnaire and prevalence estimates.

Authors:  C H Roux; A Saraux; B Mazieres; J Pouchot; J Morvan; B Fautrel; J Testa; P Fardellone; A C Rat; J Coste; F Guillemin; L Euller-Ziegler
Journal:  Ann Rheum Dis       Date:  2007-12-12       Impact factor: 19.103

Review 3.  OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009.

Authors:  W Zhang; G Nuki; R W Moskowitz; S Abramson; R D Altman; N K Arden; S Bierma-Zeinstra; K D Brandt; P Croft; M Doherty; M Dougados; M Hochberg; D J Hunter; K Kwoh; L S Lohmander; P Tugwell
Journal:  Osteoarthritis Cartilage       Date:  2010-02-11       Impact factor: 6.576

Review 4.  Epidemiology of hip and knee osteoarthritis.

Authors:  D T Felson
Journal:  Epidemiol Rev       Date:  1988       Impact factor: 6.222

5.  Prevalence of hip osteoarthritis in Iceland.

Authors:  T Ingvarsson; G Hägglund; L S Lohmander
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

6.  Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events.

Authors:  Andrew T Chan; JoAnn E Manson; Christine M Albert; Claudia U Chae; Kathryn M Rexrode; Gary C Curhan; Eric B Rimm; Walter C Willett; Charles S Fuchs
Journal:  Circulation       Date:  2006-03-13       Impact factor: 29.690

7.  Lifetime nonnarcotic analgesic use and decline in renal function in women.

Authors:  Gary C Curhan; Eric L Knight; Bernard Rosner; Susan E Hankinson; Meir J Stampfer
Journal:  Arch Intern Med       Date:  2004-07-26

8.  Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997.

Authors:  Edward Yelin; Louise Murphy; Miriam G Cisternas; Aimee J Foreman; David J Pasta; Charles G Helmick
Journal:  Arthritis Rheum       Date:  2007-05

9.  Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec, Canada.

Authors:  Elham Rahme; Alan Barkun; Hacene Nedjar; Sabine Gaugris; Douglas Watson
Journal:  Am J Gastroenterol       Date:  2008-03-26       Impact factor: 10.864

Review 10.  Osteoarthritis: new insights. Part 1: the disease and its risk factors.

Authors:  D T Felson; R C Lawrence; P A Dieppe; R Hirsch; C G Helmick; J M Jordan; R S Kington; N E Lane; M C Nevitt; Y Zhang; M Sowers; T McAlindon; T D Spector; A R Poole; S Z Yanovski; G Ateshian; L Sharma; J A Buckwalter; K D Brandt; J F Fries
Journal:  Ann Intern Med       Date:  2000-10-17       Impact factor: 25.391

View more
  3 in total

Review 1.  Viscosupplementation for hip osteoarthritis: Does systematic review of patient-reported outcome measures support use?

Authors:  Alexander J Acuña; Linsen T Samuel; Stacy H Jeong; Ahmed K Emara; Atul F Kamath
Journal:  J Orthop       Date:  2020-03-25

2.  Hybrid Hyaluronic Acid versus High Molecular Weight Hyaluronic Acid for the Treatment of Hip Osteoarthritis in Overweight/Obese Patients.

Authors:  Dalila Scaturro; Fabio Vitagliani; Pietro Terrana; Sofia Tomasello; Vincenzo Falco; Daniele Cuntrera; Italia Spoto; Massimo Midiri; Giulia Letizia Mauro
Journal:  J Funct Morphol Kinesiol       Date:  2022-02-09

3.  Psoralen Protects Chondrocytes, Exhibits Anti-Inflammatory Effects on Synoviocytes, and Attenuates Monosodium Iodoacetate-Induced Osteoarthritis.

Authors:  Chunli Wang; Mohanad Kh Al-Ani; Yongqiang Sha; Qingjia Chi; Nianguo Dong; Li Yang; Kang Xu
Journal:  Int J Biol Sci       Date:  2019-01-01       Impact factor: 6.580

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.